• Explore /
  • Poster
  • / INTERCEPT Program of circulating tumor DNA (ctDNA) testing for minimal residual disease (MRD) in colorectal cancer (CRC): Results from a prospective clinical cohort.

INTERCEPT Program of circulating tumor DNA (ctDNA) testing for minimal residual disease (MRD) in colorectal cancer (CRC): Results from a prospective clinical cohort.

Abstract Poster

Authors

null

Giulia Maddalena

Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Giulia Maddalena , Andrew Jared Pellatt , Madhulika Eluri , Christine Megerdichian Parseghian , Kathryn Aziz , Kristin Alfaro , Robert J. Kell , Alisha Heather Bent , Ryan W Huey , Abhineet Uppal , Tsuyoshi Konishi , Michael J. Overman , Maria Pia Morelli , Jason Willis , John Paul Y.C. Shen , Kanwal Pratap Singh Raghav , Timothy E. Newhook , Van K. Morris II, Arvind Dasari , Scott Kopetz

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Cancers of the Colon, Rectum, and Anus

Track

Colorectal Cancer,Anal Cancer

Sub Track

Diagnostics

Citation

J Clin Oncol 42, 2024 (suppl 3; abstr 27)

DOI

10.1200/JCO.2024.42.3_suppl.27

Abstract #

27

Poster Bd #

C8

Abstract Disclosures

Similar Posters

First Author: Arvind Dasari

Poster

2022 ASCO Gastrointestinal Cancers Symposium

Minimal residual disease assessment in colorectal cancer (MiRDA-C).

Minimal residual disease assessment in colorectal cancer (MiRDA-C).

First Author: Arvind Dasari

First Author: Yoshiaki Nakamura

First Author: Andrew Jared Pellatt